AdOM Advanced Optical Methods

Company Overview

Snapshot

Founded in March 2008 by Alon Harris and Yosi Weitzman, AdOM Advanced Optical Methods operates with 11–50 employees. The company has raised $1 million across one funding round. In July 2022, AdOM announced a study with Sheba Hospital using its Tear Film Imager for COVID-19 detection, achieving 91% sensitivity.

Business overview

AdOM Advanced Optical Methods specializes in developing thin-film optical imaging technologies for clinical ophthalmology, focusing on spectral imaging. The company's core product is the Tear Film Imager (TFI), designed to measure clinically relevant parameters of tear film dynamics using spectral interference to image the corneal surface. AdOM serves the healthcare and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices, Digital Healthcare, and Digital Medical Diagnostics.

Strategic signal

In July 2022, AdOM Advanced Optical Methods announced a study with Sheba Hospital demonstrating that its Tear Film Imager (TFI) achieved 91% sensitivity in diagnosing COVID-19 through a 40-second eye exam. This development signals the potential for the company's optical imaging technology to extend beyond its primary application in dry eye syndrome diagnosis, opening new avenues for rapid, non-invasive diagnostic tools in broader medical contexts and validating the versatility of its platform.

Company Intelligence Q&A

What is AdOM Advanced Optical Methods' primary product?

AdOM Advanced Optical Methods' primary product is the Tear Film Imager (TFI), a device that uses spectral interference to image the corneal surface and measure tear film dynamics for diagnosing dry eye syndrome.

When was AdOM Advanced Optical Methods founded?

AdOM Advanced Optical Methods was founded in March 2008.

What was the outcome of the COVID-19 detection study using the Tear Film Imager?

In July 2022, a study conducted with Sheba Hospital demonstrated that AdOM Advanced Optical Methods' Tear Film Imager (TFI) achieved 91% sensitivity in diagnosing COVID-19 through a 40-second eye exam.

What is the total capital raised by AdOM Advanced Optical Methods?

AdOM Advanced Optical Methods has raised a total of $1 million across one funding round.

Which medical condition does AdOM's technology primarily address?

AdOM Advanced Optical Methods' technology primarily focuses on improving the diagnosis and treatment of dry eye disease by imaging the tear film.